• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Obstetrics

Quick Take: Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma

byAliya Ramjaun
April 27, 2019
in Obstetrics, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

RELATED REPORTS

Intraperitoneal chemotherapy improves advanced ovarian cancer survival [Classics Series]

#VisualAbstract: Pretreatment with radiotherapy and two cycles of concurrent cisplatin may reduce toxicity in locally advanced nasopharyngeal carcinoma

#VisualAbstract: Trastuzumab does not improve survival in patients with esophageal adenocarcinoma with HER2 overexpression

Recent advances have been demonstrated with the administration of intraperitoneal (IP) cisplatin and paclitaxel, where women with stage III ovarian disease conferred additional survival benefit as compared to conventional intravenous (IV) chemotherapy. However, due to concerns surrounding toxicity and difficulty administering IP therapy, less than half of the eligible women treated at National Cancer Institute (NCI) comprehensive cancer centers have received it. This points to a need for a less complicated, less toxic, and more feasible outpatient regimen to increase access. In this randomized controlled trial, 1560 patients with newly diagnosed advanced ovarian carcinoma were randomly assigned to receive IV carboplatin, IP carboplatin, or IP cisplatin to evaluate the impact of two different IP chemotherapy regimens on progression-free survival (PFS). The specific treatment regimens consisted of the following: 1) 6 cycles of IV paclitaxel 80 mg/m2 once weekly with IV carboplatin, 2) IV paclitaxel 80 mg/m2 once weekly with IP carboplatin, or 3) once every 3 weeks IV paclitaxel 135 mg/m2 over 3 hours day 1, IP cisplatin 75 mg/m2 day 2, and IP paclitaxel 60 mg/m2 day 8. All participants received bevacizumab 15 mg/kg IV every 3 weeks in cycles 2 to 22. Researchers found that the median PFS duration was 24.9 months in the IV carboplatin arm, 27.4 months in the IP carboplatin arm, and 26.2 months in the IP cisplatin arm. For the subgroup of 1,380 patients with stage II/III and residual disease of 1 cm or less, median PFS was 26.9 months (IV-carboplatin), 28.7 months (IP-carboplatin), and 27.8 months (IP cisplatin), respectively. Compared to IV carboplatin, time to first progression or death was 7.5% lower in the IP carboplatin arm (HR 0.925, 95% CI 0.802 to 1.07) and 2.3% lower in the IP cisplatin arm (HR 0.977, 95% CI 0.847 to 1.13); neither of these differences were statistically significant. The median PFS for patients with stage II/III and no residual disease was 35.9 months for carboplatin, 38.8 months for IP carboplatin, and 35.5 months for IP cisplatin; again there were no statistically significant differences in this subgroup of patients. The median overall survival for all enrolled was 75.5, 78.9, and 72.9 months, respectively. The mean patient-reported Functional Assessment of Cancer Therapy neurotoxicity scores were similar for all treatment arms, however, the mean Trial Outcome Index of the Functional Assessment of Cancer Therapy-Ovary scores during chemotherapy were statistically worse in the IP cisplatin arm. In terms of safety, grade 3 of worse infections were more frequent in the IP arms (p=0.008), as was the incidence of nausea and vomiting, particularly in the IP cisplatin group at 11.0%. Grade 3 or worse hypertension was also significantly worse in the IP cisplatin arm (p<0.005) as compared to the IV carboplatin reference group. This study therefore shows that compared to IV carboplatin, PFS is not statistically increased with either IP carboplatin or IP cisplatin when combined with bevacizumab, putting into question the role of IP administration of chemotherapy in this patient population.

Click to read the study in Journal of Clinical Oncology

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: bevacizumab (Avastin)carboplatinCisplatinintraperitoneal chemotherapyovarian carcinomapaclitaxel
Previous Post

Nutrients from food, not supplements, linked to lower risks of death, cancer

Next Post

Quick Take: Levetiracetam versus phenytoin for second-line treatment of convulsive status epilepticus in children (ConSEPT)

RelatedReports

The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Hematology/Oncology Classics

Intraperitoneal chemotherapy improves advanced ovarian cancer survival [Classics Series]

June 30, 2022
#VisualAbstract: Adjuvant capecitabine improves long-term survival in early breast cancer
StudyGraphics

#VisualAbstract: Pretreatment with radiotherapy and two cycles of concurrent cisplatin may reduce toxicity in locally advanced nasopharyngeal carcinoma

May 19, 2022
#VisualAbstract: Ruxolitinib use may be associated with higher incidences of nonmelanoma skin cancers
StudyGraphics

#VisualAbstract: Trastuzumab does not improve survival in patients with esophageal adenocarcinoma with HER2 overexpression

April 27, 2022
#VisualAbstract: Delayed receipt of adjuvant hormone therapy is associated with worse survival in HR⁺, ERBB2- breast cancer
StudyGraphics

#VisualAbstract: No difference in survival between fluorouracil, cisplatin, or carboplatin-based paclitaxel therapy for locally advanced esophageal squamous cell carcinoma

March 9, 2022
Next Post
Brain lesions on MRI linked with subsequent increased stroke risk

Quick Take: Levetiracetam versus phenytoin for second-line treatment of convulsive status epilepticus in children (ConSEPT)

Paternal factors associated with short interpregnancy interval

Quick Take: Screening for breech presentation using universal late-pregnancy ultrasonography

Genetic risk assessment for Alzheimer’s disease does not increase anxiety, depression or stress

2 Minute Medicine Rewind April 29, 2019

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Cognitive behavioral therapy efficacious for treatment of comorbid posttraumatic headache and posttraumatic stress disorder symptoms among US veterans
  • Sickle cell trait associated with preexisting kidney comorbidities and increased COVID-19 mortality
  • Adding atezolizumab to standard of care treatment for human epidermal growth factor receptor 2 (HER2) positive early breast cancer does not improve pathologic response outcomes
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.